Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents

Albumin-biomineralized copper sulfide nanoparticles (Cu2−xS NPs) have attracted much attention as an emerging phototheranostic agent due to their advantages of facile preparation method and high biocompatibility. However, comprehensive preclinical safety evaluation is the only way to meet its furthe...

Full description

Bibliographic Details
Main Authors: Ding, H. (Author), Guo, H. (Author), Jiang, T. (Author), Li, X. (Author), Wang, Y. (Author), Xia, Y.-N (Author), Yang, S. (Author), Yu, H. (Author), Zhang, L.W (Author), Zhang, S. (Author), Zu, H. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 03646nam a2200613Ia 4500
001 10-1186-s12951-022-01399-5
008 220425s2022 CNT 000 0 und d
020 |a 14773155 (ISSN) 
245 1 0 |a Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents 
260 0 |b BioMed Central Ltd  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s12951-022-01399-5 
520 3 |a Albumin-biomineralized copper sulfide nanoparticles (Cu2−xS NPs) have attracted much attention as an emerging phototheranostic agent due to their advantages of facile preparation method and high biocompatibility. However, comprehensive preclinical safety evaluation is the only way to meet its further clinical translation. We herein evaluate detailedly the safety and hepatotoxicity of bovine serum albumin-biomineralized Cu2−xS (BSA@Cu2−xS) NPs with two different sizes in rats. Large-sized (LNPs, 17.8 nm) and small-sized (SNPs, 2.8 nm) BSA@Cu2−xS NPs with great near-infrared absorption and photothermal conversion efficiency are firstly obtained. Seven days after a single-dose intravenous administration, SNPs distributed throughout the body are cleared primarily through the feces, while a large amount of LNPs remained in the liver. A 14-day subacute toxicity study with a 28-day recovery period are conducted, showing long-term hepatotoxicity without recovery for LNPs but reversible toxicity for SNPs. Cellular uptake studies indicate that LNPs prefer to reside in Kupffer cells, leading to prolonged and delayed hepatotoxicity even after the cessation of NPs administration, while SNPs have much less Kupffer cell uptake. RNA-sequencing analysis for gene expression indicates that the inflammatory pathway, lipid metabolism pathway, drug metabolism-cytochrome P450 pathway, cholesterol/bile acid metabolism pathway, and copper ion transport/metabolism pathway are compromised in the liver by two sizes of BSA@Cu2−xS NPs, while only SNPs show a complete recovery of altered gene expression after NPs discontinuation. This study demonstrates that the translational feasibility of small-sized BSA@Cu2−xS NPs as excellent nanoagents with manageable hepatotoxicity. Graphical Abstract: [Figure not available: see fulltext.]. © 2022, The Author(s). 
650 0 4 |a Biocompatibility 
650 0 4 |a Biomineralization 
650 0 4 |a Biomineralization 
650 0 4 |a Bovine serum albumins 
650 0 4 |a Clinical translation 
650 0 4 |a Copper compounds 
650 0 4 |a Cu2−xS nanoagent 
650 0 4 |a Cu2−xS nanoagents 
650 0 4 |a Facile preparation 
650 0 4 |a Gene expression 
650 0 4 |a Genes expression 
650 0 4 |a Hepatotoxicity 
650 0 4 |a Hepatotoxicity 
650 0 4 |a Infrared devices 
650 0 4 |a Kupffer cells 
650 0 4 |a Light absorption 
650 0 4 |a Mammals 
650 0 4 |a Metabolism 
650 0 4 |a Metabolism pathway 
650 0 4 |a Metabolism pathway 
650 0 4 |a Metal ions 
650 0 4 |a Molecular biology 
650 0 4 |a Pathology 
650 0 4 |a Preparation method 
650 0 4 |a Recovery 
650 0 4 |a Safety evaluation 
650 0 4 |a Safety evaluations 
650 0 4 |a Sulfur compounds 
650 0 4 |a Toxicity 
700 1 |a Ding, H.  |e author 
700 1 |a Guo, H.  |e author 
700 1 |a Jiang, T.  |e author 
700 1 |a Li, X.  |e author 
700 1 |a Wang, Y.  |e author 
700 1 |a Wang, Y.  |e author 
700 1 |a Xia, Y.-N.  |e author 
700 1 |a Yang, S.  |e author 
700 1 |a Yu, H.  |e author 
700 1 |a Zhang, L.W.  |e author 
700 1 |a Zhang, S.  |e author 
700 1 |a Zu, H.  |e author 
773 |t Journal of Nanobiotechnology